Vest Financial LLC Boosts Stake in LeMaitre Vascular, Inc. $LMAT

Key Points

• Vest Financial LLC increased its stake in LeMaitre Vascular by 100.8% in Q2, owning approximately 35,177 shares valued at $2.92 million.
• LeMaitre Vascular's stock has a current market cap of $1.98 billion with a PE ratio of 42.42 and is currently trading around $87.38.
• The company recently declared a quarterly dividend of $0.20 per share, reflecting a 0.9% dividend yield and a payout ratio of 38.83%.

Vest Financial LLC grew its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 100.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 35,177 shares of the medical instruments supplier's stock after acquiring an additional 17,657 shares during the period. Vest Financial LLC owned about 0.16% of LeMaitre Vascular worth $2,921,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $26,000. Geneos Wealth Management Inc. grew its stake in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 398 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of LeMaitre Vascular in the 1st quarter worth approximately $50,000. US Bancorp DE grew its stake in shares of LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after buying an additional 368 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of LeMaitre Vascular in the 1st quarter worth approximately $168,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on LMAT shares. Weiss Ratings restated a "buy (b-)" rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Cantor Fitzgerald upped their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Barrington Research restated an "outperform" rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Tuesday, September 23rd. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $97.60.

LeMaitre Vascular Stock Performance

LMAT stock opened at $87.38 on Wednesday. The stock has a market capitalization of $1.98 billion, a PE ratio of 42.42, a price-to-earnings-growth ratio of 2.20 and a beta of 0.77. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The stock's 50 day simple moving average is $92.24 and its 200 day simple moving average is $86.40.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm's quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is presently 38.83%.

Insider Transactions at LeMaitre Vascular

In other news, Director John A. Roush sold 6,561 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at $269,875.80. This represents a 69.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the transaction, the director directly owned 2,916 shares in the company, valued at $274,104. The trade was a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 120,815 shares of company stock valued at $11,280,206 over the last 90 days. 9.50% of the stock is owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.